Discovery and Development of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide Dihydrochloride (SUVN-G3031): A Novel, Potent, Selective, and Orally Active Histamine H 3 Receptor Inverse Agonist with Robust Wake-Promoting Activity

A series of chemical optimizations guided by in vitro affinity at a histamine H receptor (H R), physicochemical properties, and pharmacokinetics in rats resulted in identification of N-[4-(1-cyclobutyl-piperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride (17v, SUVN-G3031) as a clini...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of medicinal chemistry 2019-02, Vol.62 (3), p.1203-1217
Hauptverfasser: Nirogi, Ramakrishna, Shinde, Anil, Mohammed, Abdul Rasheed, Badange, Rajesh Kumar, Reballi, Veena, Bandyala, Thrinath Reddy, Saraf, Sangram Keshari, Bojja, Kumar, Manchineella, Sravanthi, Achanta, Pramod Kumar, Kandukuri, Kiran Kumar, Subramanian, Ramkumar, Benade, Vijay, Palacharla, Raghava Choudary, Jayarajan, Pradeep, Pandey, Santoshkumar, Jasti, Venkat
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A series of chemical optimizations guided by in vitro affinity at a histamine H receptor (H R), physicochemical properties, and pharmacokinetics in rats resulted in identification of N-[4-(1-cyclobutyl-piperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride (17v, SUVN-G3031) as a clinical candidate. Compound 17v is a potent (hH R K = 8.73 nM) inverse agonist at H R with selectivity over other 70 targets, Compound 17v has adequate oral exposures and favorable elimination half-lives both in rats and dogs. It demonstrated high receptor occupancy and marked wake-promoting effects with decreased rapid-eye-movement sleep in orexin-B saporin lesioned rats supporting its potential therapeutic utility in treating human sleep disorders. It had no effect on the locomotor activity at doses several fold higher than its efficacious dose. It is devoid of hERG and phospholipidosis issues. Phase-1 evaluation for safety, tolerability, and pharmacokinetics, and long-term safety studies in animals have been successfully completed without any concern for further development.
ISSN:0022-2623
1520-4804
DOI:10.1021/acs.jmedchem.8b01280